blue cross blue shield not covering glp 1 to stop popular weight-loss drugs GLP-1 Medications 2025: Cost, Coverage

Large outcome trials such as SELECT and FLOW have shown 20 percent reductions in cardiovascular and kidney complications in high-risk adults

Beatrice Wihlander FuturHealth expands digital health platform to boost convenience for oral GLP-1 drugs Beatrice Wihlander Key takeaways FuturHealth expands its platform with oral GLP-1 drug Foundayo by Eli Lilly, offering a non-injectable option for diabetes and obesity management

In holistic native tumor microenvironment (TME) models without reconstitution, organoids from digested tissue can be mixed with collagen and injected into microfluidic systems or other culture devices to preserve the epithelium and its microenvironment in vitro

navigate_before previous navigate_next al

For support: [email protected] or [email protected] for order-related concerns